Bristol-Myers Squibb Co. (NYSE:BMY)

Pills

Short Sellers Have Mixed Feelings on Major Pharma

The short interest data have been released for the August 14 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

4 Top Pharma Stocks That Should Outperform Out To 2016

With a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back ...
Read Full Story »
fda_logo

Why the FDA Extended Review Date on Key Melanoma Drug Opdivo

Bristol-Myers Squibb Co. (NYSE: BMY) was recently featured by 24/7 Wall St. on the calendar of five key upcoming FDA events to watch in the bio-health sector. Now there is ...
Read Full Story »
Prescription drugs

Short Sellers Back Off Big Pharma

The short interest data have been released for the July 31 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
fda_logo

5 Big FDA Decisions Expected in August

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, similar to that ...
Read Full Story »
Prescription drugs

Short Sellers Run For Cover From Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress

Bristol-Myers Squibb Co. (NYSE: BMY) released its second-quarter financial results before the markets opened Thursday. The major pharmaceutical firm had $0.53 in earnings per share (EPS) on revenue of $4.2 ...
Read Full Story »
Pills

Short Sellers Run for Cover in Big Pharma

The short interest data have been released for the June 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Pills

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye? In 2014, these companies spent about $4.5 billion in advertising alone, notably ...
Read Full Story »
Pills

Short Sellers Become More Focused on Big Pharma

The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Short Sellers Back Off Big Pharma

The short interest data has been released for the May 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse sees some solid upside in big pharma in the coming years. After the health care sector has made a strong run, this firm believes that it can continue, ...
Read Full Story »
generic drugs

The 4 Overlooked Winners of ASCO

The American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to share ...
Read Full Story »
Pills

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Prescription drugs

Short Sellers Keep Strong Bets Against Big Pharma

The short interest data has been released for the April 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »